Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
Q96J92
UPID:
WNK4_HUMAN
Alternative names:
Protein kinase lysine-deficient 4; Protein kinase with no lysine 4
Alternative UPACC:
Q96J92; B0LPI0; Q8N8X3; Q8N8Z2; Q96DT8; Q9BYS5
Background:
Serine/threonine-protein kinase WNK4, also known as Protein kinase lysine-deficient 4, plays a pivotal role in the regulation of ion transport and blood pressure. It is a key component of the WNK4-SPAK/OSR1 kinase cascade, influencing the activity of various ion cotransporters and channels, thus affecting renal salt reabsorption and potassium secretion.
Therapeutic significance:
WNK4's involvement in Pseudohypoaldosteronism 2B, a disorder marked by hypertension and hyperkalemia, underscores its therapeutic potential. Targeting WNK4 could lead to innovative treatments for this condition, leveraging its role in modulating ion transport and blood pressure.